Circuit Clinical Adds Big Data/AI Capabilities with CUBRC
Circuit Clinical, www.circuitclinical.com, one of the nation’s largest integrated research organizations dedicated to empowering patients to choose clinical research as a care option, announced a strategic partnership with CUBRC, a company specializing in advanced data analytics, information fusion and biomedical sciences. The agreement will combine both Circuit Clinical’s physician network and TrialScout, www.trialscout.com, a patient engagement platform, with CUBRC’s expertise in data sciences and the development and deployment of analytical software tools.
“This remarkable partnership completes Circuit Clinical’s comprehensive offering for creating and catalyzing the deep life science dataset that’s needed to drive the discovery of new medicines,” said Dr. Irfan Khan, CEO of Circuit Clinical. “With our foundational commitment to patient privacy and data ownership, our Physician Network partners and TrialScout already enable us to directly engage patients who are interested in donating their genomic and health data in a transparent and empowering manner. Our recently announced partnership with University at Buffalo Biorepository provides Circuit Clinical with the ability to sequence and store these donated biosamples. Now our collaboration with CUBRC will let us analyze all of the datasets we collect using a state-of-the-art HIPAA-compliant platform and an expert data science team as partners. This is a bold new approach for driving the discovery of new medicines.”
The strategic partnership is expected to:
- Provide Circuit Clinical access to CUBRC’s Heartwood Analytics machine learning platform to drive new insights and potential targets for drug discovery;
- Enable Circuit Clinical and CUBRC to partner on novel NIH and DoD data science projects in healthcare and information technology; and
- Complete the population health capabilities of Circuit Clinical as it addresses building scaled collections of clinical and genomic life science datasets.
CUBRC’s healthcare informatics team, led by Dr. John Coles, is collaborating with physicians, insurers, and medical device manufacturers to develop predictive analytic methods designed to improve patient outcomes while managing cost. “This partnership will enable CUBRC to apply its machine learning and artificial intelligence platforms to sets to provide high-confidence predictions of overall efficacy and individual patient response to new therapies.” said Mike Moskal, CUBRC’s CIO and Senior Vice President of the Information Exploitation Sector.
For more information, visit www.cubrc.org
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
